 Tellen Bennett
Concepts (358)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries, Traumatic | 15 | 2023 | 341 | 4.950 |
Why?
| | Sepsis | 14 | 2025 | 557 | 4.220 |
Why?
| | Intensive Care Units, Pediatric | 18 | 2025 | 200 | 3.720 |
Why?
| | Intracranial Pressure | 7 | 2022 | 46 | 2.570 |
Why?
| | Brain Injuries | 8 | 2018 | 468 | 2.320 |
Why?
| | Machine Learning | 7 | 2025 | 447 | 2.180 |
Why?
| | Child | 71 | 2025 | 20806 | 1.910 |
Why?
| | Intracranial Hypertension | 4 | 2022 | 37 | 1.870 |
Why?
| | Hospital Mortality | 16 | 2025 | 844 | 1.780 |
Why?
| | Shock, Septic | 8 | 2024 | 206 | 1.660 |
Why?
| | Decision Support Systems, Clinical | 4 | 2023 | 206 | 1.650 |
Why?
| | Critical Care | 6 | 2023 | 544 | 1.610 |
Why?
| | Pediatrics | 6 | 2024 | 1062 | 1.490 |
Why?
| | Aftercare | 4 | 2024 | 206 | 1.410 |
Why?
| | Seizures | 3 | 2018 | 399 | 1.340 |
Why?
| | Databases, Factual | 15 | 2023 | 1279 | 1.270 |
Why?
| | Severity of Illness Index | 7 | 2025 | 2739 | 1.250 |
Why?
| | Child, Preschool | 35 | 2025 | 10451 | 1.220 |
Why?
| | Respiration, Artificial | 7 | 2024 | 601 | 1.200 |
Why?
| | Infant | 34 | 2025 | 8993 | 1.200 |
Why?
| | Critical Illness | 10 | 2025 | 736 | 1.170 |
Why?
| | Humans | 113 | 2025 | 129136 | 1.090 |
Why?
| | Outpatients | 7 | 2024 | 367 | 1.030 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 268 | 0.970 |
Why?
| | Retrospective Studies | 35 | 2025 | 14571 | 0.960 |
Why?
| | Blood Culture | 1 | 2025 | 21 | 0.960 |
Why?
| | Multiple Organ Failure | 8 | 2024 | 121 | 0.920 |
Why?
| | Recovery of Function | 3 | 2019 | 648 | 0.880 |
Why?
| | Bacterial Infections | 2 | 2024 | 229 | 0.880 |
Why?
| | Adolescent | 37 | 2025 | 20302 | 0.850 |
Why?
| | Bacteremia | 1 | 2025 | 194 | 0.820 |
Why?
| | Connective Tissue Diseases | 1 | 2023 | 81 | 0.770 |
Why?
| | Hospitalization | 9 | 2024 | 2077 | 0.750 |
Why?
| | Electronic Health Records | 9 | 2024 | 976 | 0.740 |
Why?
| | Male | 52 | 2025 | 63203 | 0.730 |
Why?
| | Infant, Newborn | 16 | 2025 | 5739 | 0.720 |
Why?
| | Female | 54 | 2025 | 68519 | 0.710 |
Why?
| | Wounds and Injuries | 5 | 2019 | 719 | 0.690 |
Why?
| | Trauma Severity Indices | 3 | 2017 | 106 | 0.680 |
Why?
| | Forecasting | 2 | 2021 | 358 | 0.680 |
Why?
| | Patient Discharge | 10 | 2024 | 857 | 0.640 |
Why?
| | Disability Evaluation | 2 | 2018 | 291 | 0.630 |
Why?
| | Pandemics | 5 | 2023 | 1492 | 0.600 |
Why?
| | Tranexamic Acid | 1 | 2018 | 37 | 0.590 |
Why?
| | Specialties, Surgical | 1 | 2019 | 78 | 0.590 |
Why?
| | Organ Dysfunction Scores | 6 | 2024 | 44 | 0.580 |
Why?
| | Hypothermia, Induced | 1 | 2018 | 73 | 0.570 |
Why?
| | Algorithms | 5 | 2024 | 1621 | 0.560 |
Why?
| | Neurophysiological Monitoring | 1 | 2017 | 10 | 0.560 |
Why?
| | Child Health | 1 | 2019 | 146 | 0.550 |
Why?
| | Neurosurgical Procedures | 2 | 2023 | 172 | 0.540 |
Why?
| | Nurses | 1 | 2019 | 164 | 0.540 |
Why?
| | Computer Security | 2 | 2021 | 19 | 0.530 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 305 | 0.520 |
Why?
| | United States | 18 | 2025 | 13941 | 0.520 |
Why?
| | Chronic Disease | 2 | 2022 | 1707 | 0.510 |
Why?
| | Health Services Research | 1 | 2019 | 389 | 0.510 |
Why?
| | Cohort Studies | 13 | 2024 | 5407 | 0.510 |
Why?
| | Health Status Indicators | 1 | 2016 | 169 | 0.500 |
Why?
| | Patient Readmission | 2 | 2018 | 668 | 0.480 |
Why?
| | Anticonvulsants | 1 | 2017 | 198 | 0.480 |
Why?
| | Phenotype | 7 | 2024 | 3058 | 0.470 |
Why?
| | Physicians | 1 | 2023 | 861 | 0.470 |
Why?
| | Medical Record Linkage | 2 | 2015 | 60 | 0.470 |
Why?
| | Medical Records Systems, Computerized | 1 | 2015 | 93 | 0.460 |
Why?
| | Child, Hospitalized | 1 | 2015 | 48 | 0.460 |
Why?
| | Electroencephalography | 1 | 2017 | 396 | 0.460 |
Why?
| | Spinal Injuries | 1 | 2015 | 52 | 0.460 |
Why?
| | Glasgow Coma Scale | 5 | 2023 | 170 | 0.460 |
Why?
| | Models, Biological | 1 | 2021 | 1695 | 0.440 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 135 | 0.430 |
Why?
| | Prospective Studies | 11 | 2024 | 7079 | 0.430 |
Why?
| | Mannitol | 2 | 2022 | 35 | 0.430 |
Why?
| | Saline Solution, Hypertonic | 2 | 2022 | 40 | 0.430 |
Why?
| | Supervised Machine Learning | 3 | 2023 | 17 | 0.420 |
Why?
| | Hypertension | 1 | 2022 | 1243 | 0.420 |
Why?
| | Software | 1 | 2018 | 610 | 0.420 |
Why?
| | Decision Support Techniques | 1 | 2017 | 405 | 0.410 |
Why?
| | Speech Therapy | 1 | 2013 | 21 | 0.410 |
Why?
| | Macrophage Activation Syndrome | 1 | 2012 | 21 | 0.410 |
Why?
| | Adenosine Monophosphate | 2 | 2024 | 62 | 0.400 |
Why?
| | Emergency Service, Hospital | 3 | 2021 | 1973 | 0.400 |
Why?
| | Alanine | 2 | 2024 | 141 | 0.390 |
Why?
| | Arthritis, Juvenile | 1 | 2012 | 54 | 0.390 |
Why?
| | Risk Factors | 11 | 2024 | 9769 | 0.390 |
Why?
| | Physical Therapy Specialty | 1 | 2013 | 51 | 0.390 |
Why?
| | Injury Severity Score | 5 | 2018 | 518 | 0.390 |
Why?
| | Ferritins | 1 | 2011 | 58 | 0.380 |
Why?
| | Occupational Therapy | 1 | 2013 | 85 | 0.370 |
Why?
| | Brain | 2 | 2014 | 2628 | 0.360 |
Why?
| | Fluid Therapy | 1 | 2012 | 135 | 0.350 |
Why?
| | Models, Statistical | 1 | 2014 | 626 | 0.340 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 517 | 0.340 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2010 | 49 | 0.340 |
Why?
| | Inpatients | 2 | 2022 | 464 | 0.340 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2012 | 250 | 0.330 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 107 | 0.320 |
Why?
| | Antiviral Agents | 3 | 2024 | 706 | 0.310 |
Why?
| | Length of Stay | 4 | 2023 | 1124 | 0.310 |
Why?
| | Prognosis | 5 | 2022 | 3788 | 0.300 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2541 | 0.290 |
Why?
| | Adult | 25 | 2024 | 35513 | 0.290 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2010 | 225 | 0.290 |
Why?
| | Systemic Inflammatory Response Syndrome | 3 | 2024 | 84 | 0.290 |
Why?
| | Proteome | 2 | 2022 | 431 | 0.280 |
Why?
| | Antibodies, Monoclonal | 5 | 2024 | 1361 | 0.270 |
Why?
| | Infant Equipment | 1 | 2006 | 8 | 0.270 |
Why?
| | Survival Rate | 4 | 2019 | 1875 | 0.270 |
Why?
| | Comorbidity | 2 | 2022 | 1547 | 0.270 |
Why?
| | Protective Devices | 1 | 2006 | 30 | 0.260 |
Why?
| | Logistic Models | 5 | 2024 | 1979 | 0.260 |
Why?
| | Antibodies, Viral | 3 | 2024 | 603 | 0.250 |
Why?
| | Accidents, Traffic | 2 | 2006 | 187 | 0.250 |
Why?
| | Transcriptome | 2 | 2022 | 884 | 0.250 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2016 | 46 | 0.240 |
Why?
| | Disease Progression | 5 | 2023 | 2613 | 0.240 |
Why?
| | Qualitative Research | 2 | 2023 | 1231 | 0.230 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 281 | 0.230 |
Why?
| | Biological Science Disciplines | 1 | 2024 | 16 | 0.220 |
Why?
| | Knowledge Bases | 1 | 2024 | 22 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 58 | 0.220 |
Why?
| | Middle Aged | 13 | 2024 | 31080 | 0.220 |
Why?
| | Wearable Electronic Devices | 1 | 2024 | 43 | 0.220 |
Why?
| | Accelerometry | 1 | 2024 | 91 | 0.220 |
Why?
| | Pattern Recognition, Automated | 1 | 2024 | 72 | 0.220 |
Why?
| | Employment | 1 | 2024 | 167 | 0.210 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 48 | 0.210 |
Why?
| | Microscopy | 2 | 2021 | 140 | 0.200 |
Why?
| | Heart Failure | 3 | 2023 | 2158 | 0.200 |
Why?
| | Aged | 11 | 2024 | 22090 | 0.200 |
Why?
| | Lower Extremity | 1 | 2006 | 404 | 0.200 |
Why?
| | ROC Curve | 3 | 2024 | 502 | 0.200 |
Why?
| | Quality of Life | 2 | 2024 | 2694 | 0.190 |
Why?
| | Brain Diseases | 1 | 2023 | 135 | 0.190 |
Why?
| | Mobile Applications | 1 | 2024 | 159 | 0.190 |
Why?
| | Vital Signs | 1 | 2022 | 41 | 0.190 |
Why?
| | Blood | 1 | 2022 | 100 | 0.190 |
Why?
| | Global Health | 1 | 2024 | 328 | 0.190 |
Why?
| | Blood Pressure Determination | 1 | 2022 | 150 | 0.190 |
Why?
| | Creatine | 1 | 2001 | 55 | 0.190 |
Why?
| | Young Adult | 8 | 2024 | 12389 | 0.190 |
Why?
| | Ventricular Pressure | 1 | 2001 | 43 | 0.180 |
Why?
| | Myocarditis | 1 | 2022 | 98 | 0.180 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3033 | 0.180 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 55 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2024 | 248 | 0.180 |
Why?
| | Survivors | 2 | 2022 | 463 | 0.180 |
Why?
| | Respiratory Insufficiency | 1 | 2024 | 313 | 0.180 |
Why?
| | Veins | 1 | 2001 | 59 | 0.180 |
Why?
| | Age Distribution | 1 | 2022 | 376 | 0.180 |
Why?
| | Focus Groups | 1 | 2023 | 455 | 0.180 |
Why?
| | Morbidity | 1 | 2022 | 302 | 0.180 |
Why?
| | Common Data Elements | 1 | 2020 | 12 | 0.180 |
Why?
| | Fractures, Bone | 1 | 2006 | 419 | 0.180 |
Why?
| | Body Temperature | 1 | 2001 | 216 | 0.180 |
Why?
| | Washington | 2 | 2011 | 148 | 0.180 |
Why?
| | Acute Lung Injury | 1 | 2023 | 264 | 0.180 |
Why?
| | Early Diagnosis | 1 | 2022 | 236 | 0.180 |
Why?
| | Intersectoral Collaboration | 1 | 2021 | 61 | 0.180 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 91 | 0.170 |
Why?
| | Risk Assessment | 4 | 2024 | 3260 | 0.170 |
Why?
| | Monitoring, Ambulatory | 1 | 2001 | 84 | 0.170 |
Why?
| | Interferons | 1 | 2022 | 192 | 0.170 |
Why?
| | Physical Exertion | 1 | 2001 | 212 | 0.170 |
Why?
| | Databases, Genetic | 1 | 2021 | 228 | 0.170 |
Why?
| | Hypoxia | 2 | 2024 | 1036 | 0.170 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2021 | 538 | 0.170 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 335 | 0.170 |
Why?
| | Registries | 2 | 2018 | 1884 | 0.160 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 239 | 0.160 |
Why?
| | Hemodynamics | 2 | 2001 | 1084 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2023 | 220 | 0.160 |
Why?
| | Neurosurgeons | 1 | 2019 | 18 | 0.160 |
Why?
| | Acute Disease | 1 | 2022 | 968 | 0.160 |
Why?
| | Dexamethasone | 1 | 2021 | 340 | 0.160 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 221 | 0.160 |
Why?
| | Medicine | 1 | 2020 | 117 | 0.150 |
Why?
| | Information Dissemination | 1 | 2021 | 204 | 0.150 |
Why?
| | Critical Care Nursing | 1 | 2019 | 36 | 0.150 |
Why?
| | Regression Analysis | 2 | 2017 | 984 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2017 | 4915 | 0.150 |
Why?
| | Programming Languages | 1 | 2018 | 22 | 0.150 |
Why?
| | Intensive Care Units | 2 | 2023 | 719 | 0.150 |
Why?
| | Metabolome | 1 | 2021 | 319 | 0.150 |
Why?
| | Immunohistochemistry | 2 | 2020 | 1671 | 0.150 |
Why?
| | User-Computer Interface | 1 | 2019 | 148 | 0.150 |
Why?
| | Maternal-Child Health Centers | 1 | 1997 | 9 | 0.150 |
Why?
| | National Health Programs | 1 | 1997 | 18 | 0.150 |
Why?
| | Caregivers | 1 | 2024 | 812 | 0.140 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 254 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1496 | 0.130 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2016 | 14 | 0.130 |
Why?
| | Hyperlipoproteinemia Type I | 1 | 2016 | 7 | 0.130 |
Why?
| | Cause of Death | 2 | 2018 | 393 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 774 | 0.130 |
Why?
| | Oxygen | 1 | 2001 | 902 | 0.130 |
Why?
| | Pneumonia | 1 | 2022 | 599 | 0.130 |
Why?
| | Interviews as Topic | 1 | 2019 | 717 | 0.130 |
Why?
| | Antibodies, Neutralizing | 3 | 2022 | 264 | 0.130 |
Why?
| | Propensity Score | 1 | 2017 | 265 | 0.130 |
Why?
| | Cell Nucleus | 1 | 2019 | 579 | 0.130 |
Why?
| | Biomarkers | 2 | 2024 | 3897 | 0.130 |
Why?
| | Trauma Centers | 2 | 2016 | 410 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2024 | 10227 | 0.130 |
Why?
| | Retinal Diseases | 1 | 2016 | 86 | 0.120 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 79 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2016 | 126 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 1825 | 0.120 |
Why?
| | Blood Pressure | 1 | 2022 | 1735 | 0.120 |
Why?
| | Comparative Effectiveness Research | 1 | 2016 | 151 | 0.120 |
Why?
| | Organizational Culture | 1 | 2016 | 137 | 0.120 |
Why?
| | Military Personnel | 1 | 2001 | 518 | 0.120 |
Why?
| | Women's Health | 1 | 1997 | 364 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2014 | 39 | 0.110 |
Why?
| | Area Under Curve | 1 | 2014 | 282 | 0.110 |
Why?
| | Mass Screening | 1 | 2021 | 1159 | 0.110 |
Why?
| | Exercise | 1 | 2024 | 1950 | 0.100 |
Why?
| | Patient Safety | 1 | 2016 | 291 | 0.100 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1210 | 0.100 |
Why?
| | Deglutition | 1 | 2013 | 67 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1270 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2012 | 92 | 0.100 |
Why?
| | Cyclosporine | 1 | 2012 | 169 | 0.100 |
Why?
| | Cyclophosphamide | 1 | 2012 | 232 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1671 | 0.100 |
Why?
| | Time Factors | 4 | 2019 | 6518 | 0.100 |
Why?
| | Medical Audit | 1 | 2011 | 77 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2016 | 608 | 0.090 |
Why?
| | Datasets as Topic | 2 | 2022 | 110 | 0.090 |
Why?
| | Gastrostomy | 1 | 2012 | 112 | 0.090 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2014 | 261 | 0.090 |
Why?
| | Tracheostomy | 1 | 2012 | 119 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2023 | 3342 | 0.090 |
Why?
| | Aged, 80 and over | 2 | 2021 | 7066 | 0.080 |
Why?
| | Data Collection | 3 | 2022 | 650 | 0.080 |
Why?
| | Patient Transfer | 1 | 2011 | 164 | 0.080 |
Why?
| | Consensus | 2 | 2024 | 638 | 0.080 |
Why?
| | Age Factors | 3 | 2014 | 3120 | 0.080 |
Why?
| | Interleukin-1 | 1 | 2012 | 961 | 0.080 |
Why?
| | Gestational Age | 1 | 2010 | 868 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2011 | 525 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2021 | 2437 | 0.070 |
Why?
| | Sepsis-Associated Encephalopathy | 1 | 2024 | 1 | 0.060 |
Why?
| | Incidence | 1 | 2010 | 2635 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4396 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 198 | 0.050 |
Why?
| | Respiration | 1 | 2024 | 191 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 80 | 0.050 |
Why?
| | Streptococcal Infections | 1 | 2024 | 145 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 72 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 85 | 0.050 |
Why?
| | Semicircular Canals | 1 | 1982 | 29 | 0.050 |
Why?
| | Health Insurance Portability and Accountability Act | 1 | 2022 | 12 | 0.050 |
Why?
| | International Classification of Diseases | 1 | 2023 | 124 | 0.050 |
Why?
| | Sinusitis | 1 | 2024 | 202 | 0.050 |
Why?
| | Biochemical Phenomena | 1 | 2001 | 10 | 0.050 |
Why?
| | Data Accuracy | 1 | 2022 | 59 | 0.050 |
Why?
| | Treatment Failure | 1 | 2022 | 343 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2001 | 1271 | 0.050 |
Why?
| | Health Policy | 1 | 2024 | 353 | 0.050 |
Why?
| | Time | 1 | 2001 | 75 | 0.050 |
Why?
| | Access to Information | 1 | 2021 | 47 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 372 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2024 | 862 | 0.040 |
Why?
| | Health Resources | 1 | 2022 | 120 | 0.040 |
Why?
| | Ethics Committees, Research | 1 | 2021 | 41 | 0.040 |
Why?
| | Government Regulation | 1 | 2021 | 49 | 0.040 |
Why?
| | Los Angeles | 1 | 2020 | 63 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2021 | 125 | 0.040 |
Why?
| | Data Mining | 1 | 2021 | 109 | 0.040 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 372 | 0.040 |
Why?
| | Abbreviated Injury Scale | 1 | 2019 | 22 | 0.040 |
Why?
| | Delphi Technique | 1 | 2020 | 226 | 0.040 |
Why?
| | Database Management Systems | 1 | 1999 | 48 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1210 | 0.040 |
Why?
| | Patient Admission | 1 | 2019 | 184 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 471 | 0.040 |
Why?
| | North Carolina | 1 | 1997 | 100 | 0.040 |
Why?
| | Neuroendocrine Tumors | 1 | 2019 | 99 | 0.040 |
Why?
| | Body Composition | 1 | 2001 | 657 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2022 | 718 | 0.040 |
Why?
| | Biomedical Research | 1 | 2023 | 647 | 0.040 |
Why?
| | Policy Making | 1 | 1997 | 88 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 737 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2001 | 1865 | 0.030 |
Why?
| | Fundus Oculi | 1 | 2016 | 61 | 0.030 |
Why?
| | Metabolomics | 1 | 2021 | 599 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2016 | 58 | 0.030 |
Why?
| | Research | 1 | 1999 | 410 | 0.030 |
Why?
| | Health Care Surveys | 1 | 1997 | 558 | 0.030 |
Why?
| | Remission Induction | 1 | 2016 | 271 | 0.030 |
Why?
| | Pancreatitis | 1 | 2016 | 128 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1349 | 0.030 |
Why?
| | Proteomics | 1 | 2021 | 1010 | 0.030 |
Why?
| | Health Education | 1 | 1997 | 332 | 0.030 |
Why?
| | Coroners and Medical Examiners | 1 | 1994 | 7 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1689 | 0.030 |
Why?
| | Hospitals, Low-Volume | 1 | 2014 | 22 | 0.030 |
Why?
| | Death Certificates | 1 | 1994 | 32 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2021 | 2716 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2014 | 136 | 0.030 |
Why?
| | Receptors, Pituitary Hormone-Regulating Hormone | 1 | 1993 | 8 | 0.030 |
Why?
| | Societies, Medical | 1 | 1997 | 749 | 0.030 |
Why?
| | Receptors, Neuropeptide | 1 | 1993 | 12 | 0.030 |
Why?
| | Cross Infection | 1 | 2015 | 196 | 0.030 |
Why?
| | Risk Adjustment | 1 | 2014 | 79 | 0.030 |
Why?
| | Program Evaluation | 1 | 1997 | 876 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1993 | 267 | 0.030 |
Why?
| | Public Health | 1 | 1997 | 486 | 0.030 |
Why?
| | Utah | 1 | 2011 | 65 | 0.020 |
Why?
| | Sex Factors | 2 | 2014 | 1953 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2019 | 878 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1025 | 0.020 |
Why?
| | Population Surveillance | 1 | 1994 | 428 | 0.020 |
Why?
| | Swine | 1 | 1993 | 746 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1265 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 424 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 1997 | 897 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 513 | 0.020 |
Why?
| | Goals | 1 | 2011 | 162 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2863 | 0.020 |
Why?
| | Triage | 1 | 2011 | 213 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2001 | 5377 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 1997 | 1275 | 0.020 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 297 | 0.020 |
Why?
| | Pyridoxine | 1 | 1988 | 32 | 0.020 |
Why?
| | Premenstrual Syndrome | 1 | 1988 | 34 | 0.020 |
Why?
| | Pregnancy | 1 | 1997 | 6375 | 0.010 |
Why?
| | Physical Stimulation | 1 | 1982 | 76 | 0.010 |
Why?
| | Reflex | 1 | 1982 | 68 | 0.010 |
Why?
| | Therapeutic Irrigation | 1 | 1982 | 76 | 0.010 |
Why?
| | Nausea | 1 | 1982 | 108 | 0.010 |
Why?
| | Animal Nutritional Physiological Phenomena | 1 | 1999 | 14 | 0.010 |
Why?
| | Cattle | 1 | 1999 | 963 | 0.010 |
Why?
| | Iowa | 1 | 1994 | 24 | 0.010 |
Why?
| | Receptors, Vasoactive Intestinal Peptide | 1 | 1993 | 4 | 0.010 |
Why?
| | Receptors, Calcitonin | 1 | 1993 | 3 | 0.010 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 1993 | 6 | 0.010 |
Why?
| | Growth Hormone-Releasing Hormone | 1 | 1993 | 24 | 0.010 |
Why?
| | Homicide | 1 | 1994 | 60 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1993 | 140 | 0.010 |
Why?
| | Bias | 1 | 1994 | 195 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1993 | 330 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1993 | 368 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1993 | 230 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 570 | 0.010 |
Why?
| | Accidental Falls | 1 | 1994 | 168 | 0.010 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 1993 | 206 | 0.010 |
Why?
| | Transfection | 1 | 1993 | 896 | 0.010 |
Why?
| | Base Sequence | 1 | 1993 | 2135 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1993 | 2041 | 0.000 |
Why?
| | Drug Evaluation | 1 | 1988 | 81 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1993 | 2819 | 0.000 |
Why?
| | Suicide | 1 | 1994 | 587 | 0.000 |
Why?
| | Protein Binding | 1 | 1993 | 2106 | 0.000 |
Why?
| | Drug Therapy, Combination | 1 | 1988 | 1013 | 0.000 |
Why?
| | Animals | 2 | 1999 | 34610 | 0.000 |
Why?
| | Gene Expression Regulation | 1 | 1993 | 2509 | 0.000 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|